毕赤酵母表达双价人乳头瘤病毒(16和18型)L1病毒样颗粒疫苗在9-45岁健康中国女性中的安全性和免疫原性:随机双盲安慰剂对照1期临床试验
在广西纳入160名9-45岁健康女性,按1:1:2随机接受低剂量(0.5 mL)或高剂量(1.0 mL)双价HPV疫苗或安慰剂(铝佐剂),按0、2、6月程序接种。安慰剂组、低剂量组和高剂量组不良事件报告率分别为47.5%、55.0%和55.0%,未发生严重不良事件。完成三剂接种者100%产生抗HPV 16/18中和抗体,低剂量组与高剂量组几何平均滴度相似,低剂量(0.5 mL)被选为进一步免疫原性和效力研究。
要点
- 安慰剂组、低剂量组和高剂量组不良事件报告率分别为47.5%、55.0%和55.0%,未发生严重不良事件。
- 完成三剂接种者100%产生抗HPV 16/18中和抗体。
- 低剂量(0.5 mL)被选为进一步免疫原性和效力研究。
核心结论
- 毕赤酵母表达双价HPV疫苗在9-45岁中国女性中安全且有免疫原性,低剂量(0.5 mL)被选为进一步免疫原性和效力研究。
研究设计与样本
- 随机、双盲、安慰剂对照1期临床试验,在中国广西纳入160名9-45岁健康女性。
- 按1:1:2随机接受低剂量(0.5 mL)或高剂量(1.0 mL)双价HPV疫苗或安慰剂(铝佐剂),按0、2、6月程序接种。
- 每次接种后30天内记录不良事件,第0、60、180和210天采集血清检测抗HPV 16/18中和抗体。
主要发现
- 160名参与者至少接种一剂,152名完成三剂接种。
- 安慰剂组、低剂量组和高剂量组不良事件报告率分别为47.5%、55.0%和55.0%,试验期间未发生严重不良事件。
- 完成三剂接种者100%产生抗HPV 16/18中和抗体。
- 低剂量组GMT HPV 16=10816(95%CI:7824-14953),高剂量组GMT HPV 16=14482(95%CI:10848-19333)。
- 低剂量组GMT HPV 18=3966(95%CI:2693-5841),高剂量组GMT HPV 18=3428(95%CI:2533-4639)。
临床怎么用
- 作者结论认为该毕赤酵母表达双价HPV疫苗在9-45岁中国女性中安全且有免疫原性。
- 作者将低剂量(0.5 mL)选为进一步免疫原性和效力研究。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the safety and immunogenicity of high and low doses of a novel pichia pastoris-expressed bivalent (types 16 and 18) human papillomavirus (HPV) virus-like particle vaccine. METHODS: In this randomized, double-blind, placebo-controlled phase 1 trial, we enrolled 160 healthy females aged 9-45 years in Guangxi, China who were randomized (1:1:2) to receive either low (0.5 mL) or high (1.0 mL) dosages of bivalent HPV vaccine, or placebo (aluminum adjuvant) in a 0, 2, 6 months schedule. Adverse events and other significant conditions that occurred within 30 days after each vaccination were recorded throughout the trial. Sera were collected at days 0, 60, 180 and 210 to measure anti-HPV 16/18 neutralizing antibodies. RESULTS: A total of 160 participants received at least one dose of the HPV vaccine and 152 completed the three dose vaccination series. Reporting rates of adverse events in placebo, low dose (0.5 mL) and high dose (1.0 mL) groups were 47.5 %, 55.0 % and 55.0 %, respectively. No serious adverse events occurred during this trial. 100 % of the participants who received three doses of the HPV vaccine produced neutralizing antibodies against HPV 16/18 vaccine. For HPV 16 and HPV 18, the geometric mean titers (GMTs) were similar between the low dose group (GMTHPV 16 = 10816 [95 % CI: 7824-14953]), GMTHPV 18 = 3966 [95 % CI: 2693-5841]) and high dose group (GMT HPV 16 = 14482 [95 % CI: 10848-19333], GMT HPV 18 = 3428 [95 % CI: 2533-4639]). CONCLUSION: The pichia pastoris-expressed bivalent HPV vaccine was safe and immunogenic in Chinese females aged 9-45 years. The low dosage (0.5 mL) was selected for further immunogenicity and efficacy study.
引用
- Li J, Shi LW, Yu BW, et al. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial. Vaccine. 2023. PMID: 37061370. doi:10.1016/j.vaccine.2023.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。